Johnson & Johnson: hypertension drug fails clinical trial

(CercleFinance.com) - Johnson & Johnson's Actelion said on Monday that its receptor agonist Selexipag failed to meet its primary endpoint in patients with pulmonary arterial hypertension in a late-stage clinical trial.


The 247-patient study evaluated the efficacy and safety of initial triple oral combination therapy based on selexipag compared to initial double oral combination therapy with placebo.

Although the study's primary endpoint was not met, Actelion said it observed a signal of reduced risk of disease progression in the initial triple-oral combination therapy group compared to the initial double-oral therapy group.

Copyright (c) 2020 CercleFinance.com. All rights reserved.